youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
BSX:NYSE
Boston Scientific Corp
$45.69
arrow_downward
-0.72%(-0.33) 1D
Oct 23, 4:00:04 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BSX...
Open
$45.84
High
$46.55
Low
$45.22
Mkt. cap
66.22B
Avg. vol.
18.42M
Volume
8.77M
P/E ratio
18.53
52-wk high
$105.65
52-wk low
$41.38
EPS
$2.47
Beta
0.58
Shares outstanding
1.45B
No. of employees
59K
Open
$45.84
High
$46.55
Low
$45.22
Mkt. cap
66.22B
Avg. vol.
18.42M
Volume
8.77M
P/E ratio
18.53
52-wk high
$105.65
52-wk low
$41.38
EPS
$2.47
Beta
0.58
Shares outstanding
1.45B
No. of employees
59K
News stories
From web sources and news partners
Yahoo Finance
·
2 days ago
Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics
Seeking Alpha
·
3 days ago
Boston Scientific: A Q3 Earnings Miss Likely Amid Product Recall, Cybersecurity Incident
Yahoo Finance
·
3 days ago
Boston Scientific (BSX) Stock May Be 44% Undervalued As Neuromodulation Growth Builds
WSJ
·
1 month ago
Boston Scientific Won’t Meet Guidance Due to Cyberattack
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp
CEOMichael F. Mahoney
Employees59K
FoundedJun 29, 1979
HeadquartersMarlborough, Massachusetts, United States
SectorMedical device
Websitebostonscientific.com
Analyst ratings
Based on 23 analysts giving stock ratings to BSX in the past 3 months
Strong buy
Buy
19
Hold
4
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for BSX in the last 3 months.
Highest
Current $45.69
$70.00 (+53.21%)
Average
$56.91 (+24.56%)
Lowest
$48.00 (+5.06%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Rick Wise Stifel Nicolaus | Buy | Maintained | $55.00 | +20.4% | 10/25/2026 |
William Plovanic Canaccord Genuity | Buy | Maintained | $66.00 | +44.5% | 10/22/2026 |
Richard Newitter Truist Financial | Buy | Maintained | $51.00 | +11.6% | 10/14/2026 |
Matthew O'Brien Piper Sandler | Buy | Maintained | $60.00 | +31.3% | 10/14/2026 |
Anthony Petrone Mizuho Securities | Buy | Reiterated | $55.00 | +20.4% | 10/13/2026 |
Marie Thibault BTIG | Buy | Reiterated | $56.00 | +22.6% | 10/12/2026 |
Mike Kratky Leerink Partners | Buy | Reiterated | $55.00 | +20.4% | 10/12/2026 |
Christopher Pasquale Barclays | Hold | Initiated | $48.00 | +5.1% | 10/07/2026 |
Matt Miksic Barclays | Hold | Maintained | $48.00 | +5.1% | 10/07/2026 |
Joanne Wuensch Citi | Hold | Reiterated | $48.00 | +5.1% | 10/05/2026 |
Unknown Analyst Bernstein | Buy | Reiterated | $54.00 | +18.2% | 10/02/2026 |
Robbie Marcus J.P. Morgan | Buy | Maintained | $56.00 | +22.6% | 10/01/2026 |
Kendall Au RBC Capital | Buy | Maintained | $70.00 | +53.2% | 10/01/2026 |
Larry Biegelsen Wells Fargo | Hold | Reiterated | $48.00 | +5.1% | 09/24/2026 |
Suraj Kalia Oppenheimer | Buy | Reiterated | $65.00 | +42.3% | 09/21/2026 |
Travis Steed Bank of America Securities | Buy | Maintained | $54.00 | +18.2% | 09/20/2026 |
Josh Jennings TD Cowen | Buy | Maintained | $56.00 | +22.6% | 09/17/2026 |
Matthew Taylor Jefferies | Buy | Maintained | $60.00 | +31.3% | 09/11/2026 |
David Toung Argus Research | Hold | Downgraded | - | - | 07/30/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $55.00 | +20.4% | 07/30/2026 |
Pito Chickering Deutsche Bank | Buy | Maintained | $60.00 | +31.3% | 07/30/2026 |
David Rescott Robert W. Baird | Buy | Maintained | $56.00 | +22.6% | 07/30/2026 |
Shagun Singh Chadha RBC Capital | Buy | Reiterated | $70.00 | +53.2% | 07/29/2026 |
Michael Matson Needham | Buy | Maintained | $57.00 | +24.8% | 07/29/2026 |
Patrick Wood UBS | Buy | Maintained | $67.00 | +46.6% | 07/30/2026 |
Unknown Analyst Oppenheimer | Buy | Maintained | $85.00 | +86% | 07/27/2026 |
David Roman Goldman Sachs | Buy | Maintained | $57.00 | +24.8% | 07/14/2026 |
Stephanie Elghazi Bank of America Securities | Buy | Maintained | $68.00 | +48.8% | 06/09/2026 |
Michael Polark Wolfe Research | Hold | Downgraded | - | - | 05/29/2026 |
Hans Engel Erste Group | Hold | Reiterated | - | - | 04/01/2026 |
Jayson Bedford Raymond James | Buy | Maintained | $88.00 | +92.6% | 03/27/2026 |
Danielle Antalffy UBS | Buy | Reiterated | $105.00 | +129.8% | 03/17/2026 |
Lee Hambright Bernstein | Buy | Maintained | $112.00 | +145.1% | 02/05/2026 |
Next call in 2 days
Wed, Oct 28, 2:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.72
Revenue / Est. (USD)
- / 5.05B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 5.06B | 5.29B | 5.20B | 5.44B |
Cost of goods sold | 1.54B | 1.61B | 1.60B | 1.61B |
Cost of revenue | 1.54B | 1.61B | 1.60B | 1.61B |
Research and development expenses | 514.00M | 569.00M | 516.00M | 554.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.74B | 1.83B | 1.78B | 1.80B |
Operating expense | 2.48B | 2.63B | 2.53B | 2.59B |
Total operating expenses | 4.02B | 4.24B | 4.13B | 4.20B |
Operating income | 1.05B | 1.04B | 1.07B | 1.25B |
Other non operating income | -16.00M | 28.00M | 28.00M | -6.00M |
EBT including unusual items | 938.00M | 700.00M | 1.16B | 1.06B |
EBT excluding unusual items | 935.00M | 1.01B | 999.00M | 1.14B |
Income tax expense | 183.00M | 30.00M | -176.00M | 155.00M |
Effective tax rate | 19.51% | 4.29% | -15.13% | 14.62% |
Other operating expenses | - | - | - | - |
Net income | 755.00M | 672.00M | 1.34B | 907.00M |
Net profit margin | 14.91% | 12.71% | 25.77% | 16.67% |
Earnings per share | 0.75 | 0.80 | 0.80 | 0.86 |
Interest and investment income | - | 29.00M | - | 11.00M |
Interest expense | -87.00M | -90.00M | -90.00M | -96.00M |
Net interest expenses | -87.00M | -61.00M | -90.00M | -85.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.39B | 1.41B | 1.42B | 1.60B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1